Thaler Sarah, Zorn Anna, Aster Isabell, Koliogiannis Dionysios, Renz Bernhard W, Guba Markus, Groene Philipp
Department of Anaesthesiology, LMU University Hospital, LMU Munich, Munich, Germany.
Department of General-, Visceral- and Transplant-Surgery, LMU University Hospital, LMU Munich, Munich, Germany.
Clin Transplant. 2025 May;39(5):e70179. doi: 10.1111/ctr.70179.
End-stage liver disease induces a precarious hemostatic equilibrium, named rebalanced hemostasis. Liver transplantation additionally causes profound disturbances in the hemostatic balance. Hyperfibrinolysis poses a relevant impairment to the coagulation process during liver transplantation. During surgery, the hemostatic management is guided by viscoelastic monitoring systems. The aim of this prospective, observational study was to evaluate the incidence of hyperfibrinolysis during liver transplantation using different viscoelastic assays, namely an ecarin-based test and a tissue factor-based test.
Blood sampling was done at five measurement time points during liver transplantation (T1 induction of general anesthesia, T2 start of anhepatic phase, T3 end of anhepatic phase, T4 10 min after reperfusion, T5 end of surgery). Viscoelastic testing included ClotPro assays EX-test, FIB-test, AP-test, and ECA-test. Hyperfibrinolysis was defined as a maximum lysis of at least 15%. Lysis detection time (LDT) served as an indicator for the velocity of lysis, marking the time point when less than 85% of the clot are extant.
Thirty transplantation surgeries were included. A total of 150 viscoelastic measurements have been performed. The ECA-test detected hyperfibrinolysis significantly more often (31 [21%] vs. 22 [15%] out of 150, p = 0.039) and in a higher number of patients than the EX-test. The ECA-test revealed hyperfibrinolysis significantly earlier compared to the EX-test (median LDT 2100 s [1500/2900] vs. 3300 s [2400/3800], p < 0.001).
This study demonstrates higher sensitivity of the ecarin-test than the tissue-factor-test in monitoring hyperfibrinolysis, with more frequent and earlier detection of this coagulopathy.
German Clinical Trials Register: DRKS00032827.
终末期肝病会引发一种不稳定的止血平衡,即再平衡止血。肝移植还会导致止血平衡出现严重紊乱。高纤维蛋白溶解对肝移植期间的凝血过程造成了相关损害。手术过程中,止血管理以粘弹性监测系统为指导。这项前瞻性观察性研究的目的是使用不同的粘弹性检测方法,即基于蛇毒凝血酶的检测和基于组织因子的检测,评估肝移植期间高纤维蛋白溶解的发生率。
在肝移植的五个测量时间点进行采血(T1全身麻醉诱导期,T2无肝期开始,T3无肝期结束,T4再灌注后10分钟,T5手术结束)。粘弹性检测包括ClotPro检测的EX检测、FIB检测、AP检测和ECA检测。高纤维蛋白溶解定义为最大溶解率至少为15%。溶解检测时间(LDT)作为溶解速度的指标,标记凝血块剩余少于85%的时间点。
纳入了30例移植手术。共进行了150次粘弹性测量。与EX检测相比,ECA检测更频繁地检测到高纤维蛋白溶解(150次中有31次[21%]对22次[15%],p = 0.039),且检测到高纤维蛋白溶解的患者数量更多。与EX检测相比,ECA检测更早地发现高纤维蛋白溶解(LDT中位数2100秒[1500/2900]对3300秒[2400/3800],p < 0.001)。
本研究表明,在监测高纤维蛋白溶解方面,蛇毒凝血酶检测比组织因子检测具有更高的敏感性,能更频繁、更早地检测到这种凝血病。
德国临床试验注册中心:DRKS00032827。